array(3) { ["company_details"]=> array(13) { ["name"]=> string(13) "Pharming B.V." ["slug"]=> string(20) "00474-nl-pharming-bv" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776" ["description"]=> string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates." ["address_street"]=> string(12) "Darwinweg 24" ["address_place"]=> string(6) "Leiden" ["address_region"]=> NULL ["founding_date"]=> NULL ["website_domain"]=> string(12) "pharming.com" ["website_url"]=> string(24) "https://www.pharming.com" ["industry_codes"]=> array(1) { [0]=> string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified" } ["employee_count"]=> NULL ["article_count"]=> int(54) } ["articles"]=> array(3) { [0]=> array(7) { ["title_en"]=> string(56) "Readers Competition | Especially Nasdaq popular for 2024" ["snippet_en"]=> string(139) "The annual readers' competition of Beleggers Belangen has once again produced a large number of well-known and lesser-known names for 2024." ["url"]=> string(87) "https://www.beleggersbelangen.nl/2024/01/07/vooral-nasdaq-populair-in-lezerscompetitie/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/7b876958-7628-48ac-93e0-e74c9f02fe8d" ["source"]=> string(20) "beleggersbelangen.nl" ["publication_date"]=> string(10) "2024-01-11" ["categories"]=> array(2) { [0]=> string(11) "Competition" [1]=> string(21) "Competitive Behaviour" } } [1]=> array(7) { ["title_en"]=> string(59) "Pharming rare immune disease drug will cost $550,000 a year" ["snippet_en"]=> string(134) "The Dutch biotech and pharmaceutical company Pharming chooses a high price for its new drug against the rare disorder APDS. The mid..." ["url"]=> string(123) "https://fd.nl/financiele-markten/3693272/1471881/pharming-medicijn-tegen-zeldzame-immuunziekte-gaat-550-000-per-jaar-kosten" ["image_url"]=> NULL ["source"]=> string(5) "fd.nl" ["publication_date"]=> string(10) "2023-03-27" ["categories"]=> array(1) { [0]=> string(21) "Competitive Behaviour" } } [2]=> array(7) { ["title_en"]=> string(61) "Dutch biotech company receives US approval for drug, price up" ["snippet_en"]=> string(136) "The share price of the Dutch biotech company Pharming shot up on Friday after it became known that the American medical regulator (FD..." ["url"]=> string(118) "https://fd.nl/bedrijfsleven/3693272/1471682/nederlands-biotechbedrijf-krijgt-goedkeuring-vs-voor-medicijn-koers-omhoog" ["image_url"]=> NULL ["source"]=> string(5) "fd.nl" ["publication_date"]=> string(10) "2023-03-24" ["categories"]=> array(2) { [0]=> string(21) "Competitive Behaviour" [1]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(28) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(12) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(8) } [2]=> array(2) { ["name"]=> string(10) "Insolvency" ["count"]=> int(4) } [3]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(4) } [4]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(3) } [5]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(3) } [6]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(2) } [7]=> array(2) { ["name"]=> string(21) "Financial Performance" ["count"]=> int(2) } [8]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [9]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(1) } [10]=> array(2) { ["name"]=> string(10) "Executives" ["count"]=> int(1) } [11]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(1) } [12]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(1) } [13]=> array(2) { ["name"]=> string(24) "Government Interventions" ["count"]=> int(1) } [14]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(1) } [15]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(1) } [22]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(1) } [23]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(1) } [24]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(1) } [25]=> array(2) { ["name"]=> string(5) "Debts" ["count"]=> int(1) } [26]=> array(2) { ["name"]=> string(19) "Economic Conditions" ["count"]=> int(1) } [27]=> array(2) { ["name"]=> string(7) "Economy" ["count"]=> int(1) } } } 00474-nl-pharming-bv